Pasireotide
Other / unclassified targets IGF1, IGF1R, SSTR1, SSTR2, SSTR3, SSTR5 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Signifor | — | 2012-04-24 | europa.eu ↗ |
Trials 70 · started per year
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | RECORDATI GROUP | Results RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA +5.0%, ADJUSTED NET INCOME +7.2% recordati.com ↗
Primary endpoint met in pasireotide (Signifor®) Phase 2 trial for the treatment of post -bariatric hypoglycemia (PBH); FDA meeting scheduled to discuss next steps |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | RECORDATI GROUP | RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA +5.0%, ADJUSTED NET INCOME +7.2% recordati.com ↗ |
| 2019-10-23 | RECORDATI GROUP | RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED, recordati.com ↗ |
| 2019-07-12 | RECORDATI GROUP | RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699), recordati.com ↗ |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 85 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pasireotide | “Since the importance of the IGF-signaling in PC is not only indicated by preclinical results but also by clinical efficacy of somatostatin analogs, further clinical research...” NCT01646684 ↗69“Our objective was to evaluate the short-term efficacy of the novel multireceptor ligand somatostatin analog pasireotide in patients with de novo, persistent, or recurrent...” PMID 18957506 ↗ Oct 2008 “Subcutaneous (s.c.) Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to a Matched Control Group of Healthy Volunteers” NCT01578928 ↗ “Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate).” NCT06456359 ↗ “SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days.” NCT01625520 ↗ “Pasireotide LAR (SOM230 LAR) is a cyclohexapeptide engineered to bind” PMID 26126727 ↗ Jul 2015 |
| Known as | PAS-LAR | “To assess the efficacy and safety of pasireotide long-acting release (PAS-LAR) alone or in combination with pegvisomant” PMID 29155991 ↗ Feb 2018 |
| Known as | Pasireotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | Pasireotide (as diaspartate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | Pasireotide Diaspartate | “Drug: Pasireotide Diaspartate” NCT05928390 ↗ |
| Known as | Pasireotide embonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | pasireotide LAR | “Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom...” NCT02749227 ↗5“Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).” NCT01374451 ↗ “Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.” NCT00958841 ↗ “Pasireotide LAR (SOM230 LAR) is a cyclohexapeptide engineered to bind” PMID 26126727 ↗ Jul 2015 “Pasireotide LAR (SOM230)” NCT01670110 ↗ “Drug: Pasireotide LAR” NCT01283542 ↗ |
| Known as | Pasireotide long-acting release | “Pasireotide long-acting release, with its broader binding profile and higher affinity to known somatostatin receptors, has potential for greater efficacy.” PMID 32843370 ↗ Aug 2020 |
| Known as | pasireotide pamoate | “Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate).” NCT06456359 ↗ |
| Known as | Signifor | “Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate).” NCT06456359 ↗ |
| Known as | Signifor lar | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | Signifor lar kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | SOM-230 PAMOATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | som230 | “The purpose of this study is to help us learn more about how to lower the patient's risk of the most common complications after their pancreas operation. After tumors are...” NCT00994110 ↗21“A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in...” NCT00434148 ↗ “An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (som230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients...” NCT01617733 ↗ “Pasireotide (SOM230, SIGNIFOR®) is currently indicated for the treatment of patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.” NCT02713776 ↗ “Pasireotide (SOM230), a multireceptor-targeted somatostatin analogue, has exhibited favorable safety/tolerability in several clinical studies.” PMID 24800725 ↗ May 2014 “Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes sst(1-3) and sst(5).” PMID 20410233 ↗ Apr 2010 “Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.” PMID 22282526 ↗ Jan 2012 “A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer” NCT01417806 ↗ “SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue.” NCT01372618 ↗ “Pasireotide (SOM230) s.c.Followed by Pasireotide LAR” NCT01652547 ↗ “The study evaluated SOM230 vs Placebo” NCT02619617 ↗ |
| Known as | SOM230 LAR | “SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma” NCT01329289 ↗1“Pasireotide LAR (SOM230 LAR) is a cyclohexapeptide engineered to bind” PMID 26126727 ↗ Jul 2015 |
| Action | Activate | “Somatostatin receptor 2 agonist” CHEMBL3349607 ↗1“Somatostatin receptor 3 agonist” CHEMBL3349607 ↗ |
| Action | Inhibit | “Serum cortisol levels and plasma ACTH levels were also reduced.” PMID 18957506 ↗ Oct 2008 |
| Modality | Other / unclassified | “Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog” PMID 20410233 ↗ Apr 2010 |
| Route | Subcutaneous | “each patient received pasireotide 200, 400, and 600 microg s.c. twice daily” PMID 20410233 ↗ Apr 2010 |
| Target | SSTR1 | “Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3) and 5 (SSTR5).” PMID 25376618 ↗ Nov 2014 |
| Target | SSTR2 | “Somatostatin receptor 2 agonist” CHEMBL3349607 ↗ |
| Target | SSTR3 | “Somatostatin receptor 3 agonist” CHEMBL3349607 ↗ |
| Target | SSTR5 | “Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3) and 5 (SSTR5).” PMID 25376618 ↗ Nov 2014 |